MinorTrial status: Active, Not Recruiting to Completed
Study completion date changed from estimate of Dec 29, 2025 to Nov 6, 2025
v30
MinorStudy completion date: Dec 30, 2024 to Dec 29, 2025v29
MinorStudy completion date: Dec 30, 2023 to Dec 30, 2024v28
MinorPrimary completion date changed from estimate of Dec 30, 2022 to Feb 9, 2010
Study completion date: Dec 30, 2022 to Dec 30, 2023
v27
NotablePrimary and study completion dates: Dec 30, 2021 to Dec 30, 2022v26
Show 24 earlier versionsHide 24 earlier versions
Re-verified, no change to tracked fieldsv25
NotableResults first posted: Apr 8, 2021
Primary endpoints: 3 to 2
Enrollment target: estimated 60 to confirmed 41
v24
NotablePrimary and study completion dates: Dec 2019 to Dec 30, 2021
Start date: May 1997 to May 30, 1997
v23
NotablePrimary and study completion dates: Mar 2019 to Dec 2019v22
MinorPrimary and study completion dates: Sep 2018 to Mar 2019v21
NotablePrimary completion date: Sep 2017 to Sep 2018
Study completion date: Sep 2018
v20
NotablePrimary completion date: Jul 2016 to Sep 2017v19
MinorPrimary completion date: Mar 2016 to Jul 2016v18
NotablePrimary completion date: Mar 2014 to Mar 2016
Study arms: 0 to 2
v17
NotablePrimary completion date: Mar 2013 to Mar 2014v16
MinorPrimary completion date: Oct 2012 to Mar 2013v15
MinorPrimary completion date: Oct 2012v14
NotableLead sponsor: Beckman Research Institute to City of Hope Medical Centerv13
MinorInterventions: bone marrow ablation with stem cell support (Procedure), cisplatin (Drug), conventional surgery (Procedure), cyclophosphamide (Drug)… to bone marrow ablation with stem cell support (Procedure), cisplatin (Drug), conventional surgery (Procedure), cyclophosphamide (Drug)…v12
Re-verified, no change to tracked fieldsv11
MinorInterventions: bone marrow ablation with stem cell support (Procedure), chemotherapy (Procedure), cisplatin (Drug), colony-stimulating factor therapy… to bone marrow ablation with stem cell support (Procedure), cisplatin (Drug), conventional surgery (Procedure), cyclophosphamide (Drug)…v10
Re-verified, no change to tracked fieldsv9
MinorInterventions: biological therapy (Procedure), bone marrow ablation with stem cell support (Procedure), chemotherapy (Procedure), cisplatin (Drug)… to bone marrow ablation with stem cell support (Procedure), chemotherapy (Procedure), cisplatin (Drug), colony-stimulating factor therapy…v8
MinorEnrollment target: 60
Start date: May 1997
v7
MinorTrial status: Recruiting to Active, Not Recruiting
Site details revised
v6
MinorInterventions: biological response modifier therapy (Procedure), bone marrow ablation with stem cell support (Procedure), chemotherapy (Procedure)… to biological therapy (Procedure), bone marrow ablation with stem cell support (Procedure), chemotherapy (Procedure), cisplatin (Drug)…v5
MinorInterventions: biological response modifier therapy (Procedure), bone marrow ablation with stem cell support (Procedure), chemotherapy (Procedure)… to biological response modifier therapy (Procedure), bone marrow ablation with stem cell support (Procedure), chemotherapy (Procedure)…v4
MinorInterventions: biological response modifier therapy (Procedure), bone marrow ablation with stem cell support (Procedure), chemotherapy (Procedure)… to biological response modifier therapy (Procedure), bone marrow ablation with stem cell support (Procedure), chemotherapy (Procedure)…v3
Re-verified, no change to tracked fieldsv2
Study First Submitted
Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
Minor: routine progress and housekeeping, such as sites added or enrollment closed.
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining chemotherapy with peripheral stem cell transplantation may allow the doctor to give higher doses of chemotherapy drugs and kill more tumor cells.
PURPOSE: This phase II trial is studying how well chemotherapy and stem cell transplantation work in treating patients with stage IIIB breast cancer.